1609687-29-7

Basic information

• Product Name: 4-{5-[4-(2-cyanovinyl)-2,6-dimethylphenyl]amino}-2-fluorophenylaminobenzonitrile
• CAS NO: 1609687-29-7
• Molecular Weight: 382.44
• Mol File: 1609687-29-7.mol

Chemical Properties

• CAS DataBase Reference: 4-{5-[4-(2-cyanovinyl)-2,6-dimethylphenyl]amino}-2-fluorophenylaminobenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{5-[4-(2-cyanovinyl)-2,6-dimethylphenyl]amino}-2-fluorophenylaminobenzonitrile(1609687-29-7)
• EPA Substance Registry System: 4-{5-[4-(2-cyanovinyl)-2,6-dimethylphenyl]amino}-2-fluorophenylaminobenzonitrile(1609687-29-7)

Safety Data

• Hazardous Substances Data: 1609687-29-7(Hazardous Substances Data)

Upstream product

• 1996-30-1 2-bromo-4-chloro-1-fluorobenzene 
• 500292-86-4 3-(4-amino-3,5-dimethylphenyl)acrylonitrile 
• 1155044-80-6 4-[(5-chloro-2-fluorophenyl)amino]benzonitrile 
• 873-74-5 4-Aminobenzonitrile 
• 24596-19-8 4-bromo-2,6-dimethylphenylamine 

Relevant articles and documents

2,6-Di(arylamino)-3-fluoropyridine Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors

New non-nucleoside reverse transcriptase inhibitors (NNRTI), which are similar in structure to earlier described di(arylamino)pyrimidines but featuring a 2,6-di(arylamino)-3-fluoropyridine, 2,4-di(arylamino)-5-fluoropyrimidine, or 1,3-di(arylamino)-4-fluorobenzene moiety instead of a 2,4-disubstituted pyrimidine moiety, are reported. The short and practical synthesis of novel NNRTI relies on two sequential Pd-catalyzed aminations as the key steps. It is demonstrated through direct comparison with reference compounds that the presence of a fluorine atom increases the in vitro anti-HIV activity, both against the wild type virus and drug-resistant mutant strains.

NOVEL ANTI-HIV COMPOUNDS

The present invention relates to the field of HIV-1 infections, and in particular provides novel compounds containing fluorine on the Central ring. The compounds according to this invention are very suitable for the prevention and/or treatment of HIV-1 infection and in particular show higher activity against NNRTI-resistant strains of HIV-1.